Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 1/20 | 0.37 |
| ▸ | ADSS2 | P30520 | 1/20 | 0.31 |
| ▸ | TK1 | P04183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946191 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL15071493 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL14928703 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL14945963 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL17263511 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL20126561 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL15248821 | 1.00 | RNASEL (0.37) | RNASELADSS2TK1 | |
| SCHEMBL14946187 | 0.90 | P2RY2 (0.37) | RNASEL | |
| SCHEMBL15071506 | 0.81 | PGD (0.31) | TK1 | |
| SCHEMBL15248823 | 0.81 | PGD (0.31) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193299-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160024547-A1 | MANUFACTURING METHODS FOR PRODUCTION OF RNA TRANSCRIPTS | ARES CAPITAL CORPORATION, AS AGENT | 2016-01-28 | — | — | US | disclosed |
| US-9220792-B2 | Modified polynucleotides encoding aquaporin-5 | MODERNA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9095552-B2 | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 | MODERNA THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8999380-B2 | Modified polynucleotides for the production of biologics and proteins associated with human disease | MODERNA THERAPEUTICS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8754062-B2 | DLIN-KC2-DMA lipid nanoparticle delivery of modified polynucleotides | MODERNA THERAPEUTICS, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140155472-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING ARGININOSUCCINATE SYNTHASE 1 PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140105965-A1 | MODIFIED POLYNUCLEOTIDES ENCODING COPPER METABOLISM (MURR1) DOMAIN CONTAINING 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140105964-A1 | MODIFIED POLYNUCLEOTIDES ENCODING AQUAPORIN-5 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130259924-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | modeRNA Therapeutics (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140105964-A1 | MODIFIED POLYNUCLEOTIDES ENCODING AQUAPORIN-5 | AQP1, AQP3, AQP4 | RNASEL 150/4885ADSS2 3202/4885TK1 1460/4885 |
| US-20130236974-A1 | METHOD FOR INCREASING THE PRODUCTION OF A PROTEIN OF INTEREST | IGF2BP1, PHAX, IGF2BP2 | RNASEL 242/4885ADSS2 1335/4885TK1 892/4885 |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | IGF2BP1, IGF2BP2, NSUN2 | RNASEL 222/4885ADSS2 1693/4885TK1 408/4885 |
| US-20160193299-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | RNASEL 101/4885ADSS2 1313/4885TK1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.